WithdrawnNot Applicable

Reverse Axillary Mapping in Breast Radiation Treatment Planning

Stopped: Principal Investigator decided not to move forward with the study

0Started 2021-05

Plain-language summary

The goal of this prospective study is to investigate the role of axillary reverse mapping (ARM) in radiation therapy planning of patients with breast cancer. Lymphedema is a common side effect after surgery and radiation therapy for breast cancer. The use of ARM is becoming more routine in surgery to differentiate the upper extremity lymphatics (UELs) from the breast axillary drainage to preferentially spare the UELs and reduce the rates of lymphedema.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * De novo presentation of post-operative (lumpectomy or mastectomy) female breast cancer patients to receive radiation to the whole breast or chest wall and the regional nodes. Patients who have received a sentinel lymph node (SLN) biopsy or an axillary lymph node dissection (ALND) will be eligible. * Greater than or equal to 18 years of age (no upper age limit). * Informed consent obtained. Exclusion Criteria: * Prisoners. * Patients with metastatic breast cancer. * Documented allergy to iodinated contrast * Prior breast or axillary surgeries or radiation.

What they're measuring

Delineation of the upper extremity lymphatics (UEL) during the radiation treatment planning process using axillary reverse mapping (ARM)

Timeframe: Baseline to 1 year

Trial details

NCT IDNCT04292860

SponsorUNC Lineberger Comprehensive Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-01

View on ClinicalTrials.gov More Breast Cancer trials